Our data demonstrate, for the first time, that luteolin exerts marked antitumor effects in cMet-overexpressing PDTX models of gastric cancer, at least in part via down-regulation of cMet/Akt/ERK signaling. The gene discussed is MET; the disease is gastric cancer.